Clinical trials: Prevention and Control
- Condition Prevention and Control
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Marburg Hemorrhagic Fever
Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg virus.
- Trial name
- NCT01353040
- Testing
- AVI-6003
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
The purpose of this study is to show that high-dose quadrivalent seasonal influenza vaccine (HD QIV) given together with 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) does not induce lower antibody…
- Trial name
- Engage (NCT06134804)
- Testing
- ExPEC9V, HD quadrivalent influenza vaccine
- Where
- 41 sites in United States, Belgium and 2 more
- Volunteers
- 959 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
COVID-19
Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19
Protocol bacTRL-Spike-1 will be the first-in-human study of bacTRL-Spike, and the first-in-human use of orally delivered bacTRL.
- Trial name
- NCT04334980
- Testing
- bacTRL-Spike
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Symvivo Corporation
Viral Respiratory Infection, Viral Respiratory Illnesses
A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age
Acute upper and lower respiratory infections are a major public health problem and a leading cause of morbidity and mortality worldwide.
- Trial name
- POSITS (NCT07222670)
- Testing
- INNA-051
- Where
- 6 sites in United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- ENA Respiratory Pty Ltd
Mumps, Varicella
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.
- Conditions
- Mumps, Varicella, Rubella, Measles
- Trial name
- NCT00127023
- Testing
- Measles, Mumps, Rubella and Chickenpox (live vaccine)
- Where
- 85 sites in Germany
- Volunteers
- 944 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Functional Gastrointestinal Disorders (FGIDs), Weight Loss
Effects of Multi-strain Bacillus Spore Probiotics on Growth, Digestive Function, and Gut Microbiota in Cesarean-Delivered Neonates
Infants born by cesarean section commonly show early weight loss and slower recovery of birth weight, together with characteristic patterns of gut microbiota dysbiosis marked by reduced Bifidobacterium and Bacteroides and…
- Trial name
- NCT07320287
- Testing
- RO water, LiveSpo PREG-MOM, LiveSpo CONSY
- Where
- Vietnam
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Anabio R&D
Malaria
Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.
This trial will evaluate the safety, tolerability, and immunogenicity of PfSPZ Vaccine in healthy Equatoguinean adults, adolescents, children and infants who receive doses of 0.9x10^6, 1.8x10^6 or 2.7x10^6 PfSPZ Vaccine via…
- Trial name
- NCT02859350
- Testing
- PfSPZ Vaccine, PfSPZ Challenge (for CHMI), Normal Saline
- Where
- Equatorial Guinea
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
COVID-19
Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to assess immunogenicity and safety of 202-CoV at multiple dose levels, administered as 2 injections (i.m) at 28 days apart in adult subjects 18 years of age and…
- Trial name
- NCT04990544
- Testing
- 202-CoV low adjuvant dose, 202-CoV low antigen dose, 202-CoV standard dose
- Where
- China
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Rabies Post-exposure Prophylaxis
SYN023 With Rabies Vaccine in Healthy Pediatric Subjects
This study is a randomized, double-blind, active-controlled design. The goal is to evaluate the safety, pharmacokinetics and pharmacodynamic of SYN023 in combination with rabies vaccine in healthy participants under 18 years of…
- Trial name
- NCT07342257
- Testing
- SYN023, Rabies Vaccine, HRIG
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
HIV Prevention
OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults
This is a monocentric phase I study in open-label and randomized, double-blind, placebo-controlled cohorts of HIV-1 seronegative adults to evaluate the safety, acceptability, and pharmacokinetic of OB-002H Gel administrated…
- Trial name
- NCT04791007
- Testing
- OB-002
- Where
- Poland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Orion Biotechnology Polska Sp. z o.o.
Acute Mountain Sickness (AMS)
Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
The specific aim of this double blind, randomized phase III trial is to evaluate the safety and efficacy of T89 in preventing Acute Mountain Sickness (AMS) and relieving the symptoms of AMS after rapid ascent.
- Trial name
- NCT04993729
- Testing
- T89 capsule
- Where
- 3 sites in United States, China
- Volunteers
- 853 people, healthy volunteers welcome
- Sponsor
- Tasly Pharmaceuticals, Inc.
COVID 19
Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients
More cases of COVID-19 pandemic are being reported daily around the world. It is highly infectious and, over 7 million people have been infected and more than 400,000 people have died globally till this date.
- Trial name
- HCQ-COVID19 (NCT04437693)
- Testing
- Hydroxychloroquine
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Healthy
Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults
The purpose of this study is to assess the safety, immunogenicity,and tolerability of a H5N1 Vaccine in healthy adults.
- Trial name
- NCT01250795
- Testing
- HAI-05 Influenza Vaccine, Saline
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Fraunhofer, Center for Molecular Biotechnology
Influenza Prevention
Study to Assess the Prophylactic Efficacy and Safety of Sebaloxavir Marboxil Tablets/Oral Suspension for Influenza Prevention in Household Contacts Aged ≥2 Years.
This study is a randomized, double-blind, placebo-controlled phase III clinical trial. The trial participants include index participants (IP) and household contacts (HHC).
- Trial name
- NCT07730346
- Testing
- Sebaloxavir marboxil
- Where
- China
- Volunteers
- 858 people, healthy volunteers welcome
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Weight-Gain Prevention
A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain
This is a two-week study testing the efficacy and safety of mifepristone in the prevention of olanzapine-induced weight gain in healthy male volunteers by measuring changes in body weight and BMI.
- Trial name
- NCT00455442
- Testing
- Mifepristone
- Where
- India
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Atopic Diseases
Prevention of Allergic Diseases in Infants
A multi-center, prospective, randomized, controlled, doubleblind intervention clinical Trial is performed to proof the efficiency of hydrolyzed infant formula showing a risk reduction of developing an allergy.
- Trial name
- NCT03489733
- Testing
- Hydrolyzed Formula, Control formula
- Where
- 14 sites in Bulgaria, Czechia and 8 more
- Volunteers
- 1,226 people, healthy volunteers welcome
- Sponsor
- HiPP GmbH & Co. Vertrieb KG
Yellow Fever, Rabies
A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults
The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of AVX70120 and of AVX70481 in healthy participants.
- Trial name
- SAFYR (NCT06998004)
- Testing
- AVX70120 low dose level, AVX70120 middle dose level, AVX70120 high dose level
- Where
- 2 sites in Belgium
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- AstriVax Therapeutics
Low Back Pain
Internet App to Self-Manage Occasional Low Back Pain
Nonspecific low back pain (NLBP) is the diagnosis for 85% of low back pain sufferers with no underlying medical cause (e.g., herniated disc, spinal stenosis) that requires physician care.
- Trial name
- BackPain2 (NCT01950091)
- Testing
- FitBack on-line intervention, Alternative Website Control
- Volunteers
- 606 people, healthy volunteers welcome
- Sponsor
- Oregon Center for Applied Science, Inc.
COVID-19
Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults
Phase I/II study to determine safety, tolerance and immunogenicity of EuCorVac-19, a recombinant protein vaccine, for the prevention of COVID-19 in healthy adults
- Trial name
- NCT04783311
- Testing
- EuCorVac-19, Normal Saline
- Where
- South Korea
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Influenza, Vaccine
Study of ASP7374, Cell-culture-derived Influenza Vaccine
The purpose of this study is to compare immunogenicity and safety of ASP7374 (cell-culture derived influenza vaccine) with those of approved egg-derived trivalent inactivated vaccine (TIV) in adults ≥20 and <65 years.
- Trial name
- NCT01961947
- Testing
- ASP7374, approved egg-derived TIV
- Where
- 2 sites in Japan
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.